Y-mAbs Therapeutics YMAB
$ 10.38
2.72%
Quarterly report 2024-Q3
added 11-08-2024
Country |
USA |
IPO year |
2018 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
CEO |
Dr. Claus Moller-San Pedro |
Employees in the company |
65 |
Shares |
43.6 M |
Market Cap[1] |
$ 453 M |
EBITDA (LTM) |
$ -79.4 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.